Hepatology

Normothermic machine perfusion in liver transplants improves preservation, reduces early complications, and shows promise in complex cases.

Headline results from part 1 of the phase 3 ESSENCE trial highlight semaglutide 2.4 mg’s benefits for fibrosis and steatohepatitis in patients with MASH.

Open-label, interim data from ASSURE shows positive effect and tolerability with once-daily seladelpar in patients with primary biliary cholangitis and compensated cirrhosis.

A qualitative / quantitative study shows significant gaps in PBC diagnosis confidence and skill between care providers.

Only about 2% of eligible patients with ALD have received a pharmacotherapy for alcohol use disorder—and the prescription takes more than a year to receive.

Mayo explains elafibranor’s benefit for patients with advanced-stage primary biliary cholangitis based on findings from a new ELATIVE analysis.

Data from ACG 2024 show only 1 in 12 patients eligible for second-line PBC therapy are actually doing receiving it—and it may take up to a year to initiate.

Njei points to the need for improved lean MASLD screening, citing findings from his research about its prevalence and the burden of undiagnosed disease.

The CRAC channel inhibitor zegocractin significantly improved acute pancreatitis patients' time to eating food and risk of respiratory failure in new data.

Test your knowledge of the 2024 American College of Gastroenterology alcohol-associated liver disease guidelines with this clinical quiz!

Test your knowledge of the 2024 American College of Gastroenterology focal liver lesion diagnosis and management guidelines with this clinical quiz!

Liver-related mortality in the US increased by nearly 20% from 2018, with lower transplant rates observed in states with the greatest mortality.

HCV infection was associated with elevated brachial-ankle pulse wave velocity levels in patients with ESRD receiving hemodialysis.

The FDA has extended its review of the sNDA, delaying the previous October 15, 2024, PDUFA date, without providing a new anticipated action date.

Proof-of-mechanism data from the phase 1b/2a study of WVE-006 represent the first-ever clinical demonstration of RNA editing in humans.

Compared with older nomenclature, MASLD was significantly associated with severe artery calcification.

Increased serum TBA levels at baseline significantly raised the risk of HCC development in patients with multi-etiology cirrhosis.

These data on metabolic dysfunction-associated steatotic liver disease provide information on the economic burden among high-risk patients.

The study found that, following gradual policy changes, children with acute liver failure requiring a transplant now face a reduced risk of both mortality and graft failure from 1989.

Findings highlight the potential utility of the FAST score for ruling out fibrotic MASH, pointing to the need for a sequential testing approach to rule it in.

The burden of LC-MASLD has significantly increased, especially in economically disadvantaged countries.

This analysis may help identify at-risk patients of liver enzyme elevation following sustained virologic response among individuals with hepatitis C virus infection.

A new study highlights suboptimal HDV screening rates in HBV-infected individuals, suggesting that treating HBV may improve survival for those with HDV coinfection.

Study findings showed children with both obesity and MASLD have a greater risk of youth-onset type 2 diabetes than those with obesity alone.

New phase 2b data highlight denifanstat’s impact on histological features of MASH, meeting both fibrosis improvement and MASH resolution primary endpoints.

Findings support the feasibility and clinical performance of Xpert HCV, the first FDA-approved point-of-care test for diagnosing HCV, in a nonclinical justice setting.

The designation was granted to Mirum Pharmaceuticals based on a positive interim analysis of the phase 2b VANTAGE study of volixibat.

Saggese explains the importance of second-line therapies in PBC, newly approved treatment options, and their impact on treatment goals and timelines.

Younossi explains how MASH negatively impacts patients’ quality of life and describes resmetirom’s benefit across multiple HRQoL domains.

In addition to the Breakthrough Therapy Designation, Boehringer Ingelheim announced the initiation of 2 phase 3 trials in adults with MASH and fibrosis and compensated MASH cirrhosis.